VIVOS THERAPEUTICS INC
VVOSNASDAQTrading Snapshot
- Day Range
- $0.05 β $0.06
- 52-Week Range
- $0.05 β $2.69
- Volume (shares)
- 1,435,489
- Avg Volume (shares)
- β
- Shares Outstanding
- 33.6M
- Next Earnings
- 2027-04-13
Fundamentals Snapshot
- Annual Revenue
- $17M
- Last Q Revenue
- $5M
- P/E Ratio
- β
- P/S Ratio
- 0.1x
- EPS (TTM)
- $-1.88
- Dividend Yield
- β
- Dilution (1yr)
- +57.7%
VIVOS THERAPEUTICS INC
VVOSAbout VIVOS THERAPEUTICS INC
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
βLatest News & Updates

Vivos Therapeutics Q3 Earnings Call Highlights
Vivos Therapeutics (NASDAQ: VVOS) reported lower third-quarter revenue and a narrower net loss as it reduced expenses and shifted its business toward sleep centers. The company also warned that its cash balance was insuf

Vivos Therapeutics, Inc. (VVOS) Q3 2026 Earnings Call Prepared Remarks Transcript
Vivos Therapeutics, Inc. ( VVOS ) Q3 2026 Earnings Call November 16, 2026 5:00 PM EST Company Participants Roman Franklin - Chief Financial Officer R. Huntsman - Co-Founder, Chairman of the Board & CEO Presentation Opera

Vivos Therapeutics, Inc. (VVOS) Reports Q3 Loss, Beats Revenue Estimates
Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.49 per share a year ago.

Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update
Revenue rises 24% quarter over quarter as Third quarter operating loss improves 18% year over year on cost reductions; Company regained compliance with Nasdaq stockholders' equity requirement

Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders' Equity Standard
LITTLETON, Colo., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (βVivosβ or the βCompanyβ) (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnosti

Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
Transaction Expected to Add More Than $10 Million to Stockholders' Equity as Vivos Forms Strategic Alliances Offering Potential New Revenue and Profit Opportunities Transaction Expected to Add More Than $10 Million to St